BD Q2 FY2026: Strong Results, Innovation, Shareholder Returns

Becton Dickinsons Q2 FY2026 earnings show strength with $4.7B revenue, up 2.6% YoY, and adjusted EPS of $2.90, up 3.9%. Key growth platforms like biologic drug delivery and advanced tissue regeneration posted double-digit gains. The company returned $2.3B to shareholders, including $2B in buybacks, and simplified manufacturing with 8% productivity gains. Despite tariffs impacting margins, they still beat expectations. The FDA warning letter for their El Paso plant had no safety issues, and production continues. Investors are optimistic about their new strategy and sustainable growth prospects. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/495d7564cc4316af